Bauer JH, Hefand SL: New tricks of an old molecule: lifespan regulation by p53. Aging Cell. 2006, 5: 437-440. 10.1111/j.1474-9726.2006.00228.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gasco M, Shami S, Crook T: The p53 pathway in breast cancer. Breast Cancer Res. 2002, 4: 70-76.
Article
PubMed Central
CAS
PubMed
Google Scholar
Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP: p53 mutations in colorectal cancers. Proc Natl Acad Sci USA. 1990, 87 (19): 7555-7559. 10.1073/pnas.87.19.7555.
Article
PubMed Central
CAS
PubMed
Google Scholar
Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Jeffry Evans TR, Sansom OJ: Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. PNAS. 2010, 107 (1): 246-251. 10.1073/pnas.0908428107.
Article
PubMed Central
CAS
PubMed
Google Scholar
Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, Oliff IA, Rummel MJ, Österborg A: Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukaemia. Invest New Drugs. 2008, 26 (2): 139-149. 10.1007/s10637-007-9106-z.
Article
CAS
PubMed
Google Scholar
Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B: The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol. 2011, 38 (6): 1683-1694.
CAS
PubMed
Google Scholar
Kerr JF, Harmon BV: Definition and incidence of apoptosis: an historical perspective. Apoptosis: the molecular basis of cell death. Edited by: Tomei LD, Cope FO. 1991, New York: Cold Spring Harbor Laboratory Press, 3: 5-29.
Google Scholar
Kerr JFR, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972, 26: 239-257. 10.1038/bjc.1972.33.
Article
PubMed Central
CAS
PubMed
Google Scholar
Mohan H: Textbook of pathology. 2010, New Delhi: Jaypee Brothers Medical Publishers, 21-60. 5
Google Scholar
Merkle CJ: Cellular adaptation, injury, and death. Pathophysiology: concepts of altered health states. Edited by: Porth CM, Matfin G. 2009, Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins, 94-111. 8
Google Scholar
Hacker G: The morphology of apoptosis. Cell Tissue Res. 2000, 301: 5-17. 10.1007/s004410000193.
Article
CAS
PubMed
Google Scholar
Saraste A, Pulkki K: Morphologic and biochemical hallmarks of apoptosis. Cardiovascular Res. 2000, 45: 528-537. 10.1016/S0008-6363(99)00384-3.
Article
CAS
Google Scholar
Ziegler U, Groscurth P: Morphological features of cell death. News Physiol Sci. 2004, 19: 124-128. 10.1152/nips.01519.2004.
CAS
PubMed
Google Scholar
Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, Zhivotovsky B, Blagosklonny MV, Malorni W, Knight RA, Piacentini M, Nagata S, Melino G: Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 2005, 12: 1463-1467.
Article
CAS
PubMed
Google Scholar
Manjo G, Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995, 146: 3-15.
Google Scholar
Kumar V, Abbas AK, Fausto N, Aster JC: Robins and Cotran: pathologic basis of disease. 2010, Philadelphia: Saunders Elsevier, 25-32. 8
Google Scholar
Hengartner MO: Apoptosis: corralling the corpses. Cell. 2000, 104: 325-328.
Article
Google Scholar
Vaux D, Silke J: Mammalian mitochondrial IAP-binding proteins. Biochem Biophy Res Commun. 2003, 203: 449-504.
Google Scholar
McCarthy NJ, Evan GI: Methods for detecting and quantifying apoptosis. Curr Top Dev Biol. 1998, 36: 259-278.
Article
CAS
PubMed
Google Scholar
Lavrik IN, Golks A, Krammer PH: Caspases: pharmacological manipulation of cell death. J Clin Invest. 2005, 115: 2665-2672. 10.1172/JCI26252.
Article
PubMed Central
CAS
PubMed
Google Scholar
Galluzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G: Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007, 14: 1237-1266. 10.1038/sj.cdd.4402148.
Article
CAS
Google Scholar
O'Brien MA, Kirby R: Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care. 2008, 18 (6): 572-585. 10.1111/j.1476-4431.2008.00363.x.
Article
Google Scholar
Schneider P, Tschopp J: Apoptosis induced by death receptors. Pharm Acta Helv. 2000, 74: 281-286. 10.1016/S0031-6865(99)00038-2.
Article
CAS
PubMed
Google Scholar
Karp G: Cell and molecular biology: Concepts and experiments. 2008, John New Jersey: Wiley and Sons, 653-657. 5
Google Scholar
Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell. 2004, 116 (2): 205-219. 10.1016/S0092-8674(04)00046-7.
Article
CAS
PubMed
Google Scholar
Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14; 18) chromosome translocation. Science. 1984, 226: 1097-1099. 10.1126/science.6093263.
Article
CAS
PubMed
Google Scholar
Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in haematologic malignancies. Semin Haematol. 1997, 34: 9-19.
CAS
Google Scholar
Kroemer G, Galluzzi L, Brenner C: Mitochondrial membrane permeabilisation in cell death. Physiol Rev. 2007, 87 (1): 99-163. 10.1152/physrev.00013.2006.
Article
CAS
PubMed
Google Scholar
LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG: IAP-targeted therapies for cancer. Oncogene. 2008, 27 (48): 6252-6275. 10.1038/onc.2008.302.
Article
CAS
PubMed
Google Scholar
Ghobrial IM, Witzig TE, Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005, 55: 178-194. 10.3322/canjclin.55.3.178.
Article
PubMed
Google Scholar
Szegezdi E, Fitzgerald U, Samali : Caspase-12 and ER stress mediated apoptosis: the story so far. Ann NY Acad Sci. 2003, 1010: 186-194. 10.1196/annals.1299.032.
Article
CAS
PubMed
Google Scholar
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.
Article
CAS
PubMed
Google Scholar
Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999, 13: 1899-1911. 10.1101/gad.13.15.1899.
Article
CAS
PubMed
Google Scholar
Minn AJ, Vélez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB: Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature. 1997, 385 (6614): 353-357. 10.1038/385353a0.
Article
CAS
PubMed
Google Scholar
Dewson G, Kluc RM: Bcl-2 family-regulated apoptosis in health and disease. Cell Health and Cytoskeleton. 2010, 2: 9-22.
CAS
Google Scholar
Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995, 55: 4438-
CAS
PubMed
Google Scholar
Fulda S, Meyer E, Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene. 2000, 21: 2283-2294.
Article
Google Scholar
Minn AJ, Rudin CM, Boise LH, Thompson CB: Expression of Bcl-XL can confer a multidrug resistance phenotype. Blood. 1995, 86: 1903-1910.
CAS
PubMed
Google Scholar
Miquel C, Borrini F, Grandjouan S, Aupérin A, Viguier J, Velasco V, Duvillard P, Praz F, Sabourin JC: Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Am J Clin Pathol. 2005, 23 (4): 562-570.
Article
CAS
Google Scholar
Goolsby C, Paniagua M, Tallman M, Gartenhaus RB: Bcl-2 regulatory pathway is functional in chronic lymphocytic leukaemia. Cytometry B Clin Cytom. 2005, 63 (1): 36-46.
Article
PubMed
CAS
Google Scholar
Pepper C, Hoy T, Bentley DP: Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997, 76 (7): 935-938. 10.1038/bjc.1997.487.
Article
PubMed Central
CAS
PubMed
Google Scholar
Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature. 1991, 351 (6326): 453-456. 10.1038/351453a0.
Article
CAS
PubMed
Google Scholar
Bai L, Zhu WG: p53: structure, function and therapeutic applications. J Cancer Mol. 2006, 2 (4): 141-153.
CAS
Google Scholar
Oren M, Rotter V: Introduction: p53--the first twenty years. Cell Mol Life Sci. 1999, 55: 9-11. 10.1007/s000180050265.
Article
CAS
PubMed
Google Scholar
Lane DP: p53, guardian of the genome. Nature. 1992, 358: 15-16. 10.1038/358015a0.
Article
CAS
PubMed
Google Scholar
Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, Talseth-Palmer BA, Rizos H, Zhang XD, Scott RJ, Hersey P: p53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer. 2011, 11: 203-10.1186/1471-2407-11-203.
Article
PubMed Central
CAS
PubMed
Google Scholar
Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, Williams G, Wilson M, Engelmann A, Jeffs A, Royds JA, Baird MA, Braithwaite AW: Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood. 2011, 117 (19): 5166-5177. 10.1182/blood-2010-11-321851.
Article
CAS
PubMed
Google Scholar
Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K: Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. Nucl Acids Res. 2007, 35 (6): 2093-2104. 10.1093/nar/gkm099.
Article
PubMed Central
CAS
PubMed
Google Scholar
Vucic D, Fairbrother WJ: The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res. 2007, 13 (20): 5995-6000. 10.1158/1078-0432.CCR-07-0729.
Article
CAS
PubMed
Google Scholar
Wei Y, Fan T, Yu M: Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin. 2008, 40 (4): 278-288. 10.1111/j.1745-7270.2008.00407.x.
Article
PubMed
CAS
Google Scholar
Lopes RB, Gangeswaran R, McNeish IA, Wang Y, Lemoine NR: Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer. 2007, 120 (11): 2344-2352. 10.1002/ijc.22554.
Article
CAS
PubMed
Google Scholar
Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM: MLIAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol. 2000, 10: 1359-1366. 10.1016/S0960-9822(00)00781-8.
Article
CAS
PubMed
Google Scholar
Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 2001, 495: 56-60. 10.1016/S0014-5793(01)02366-3.
Article
CAS
PubMed
Google Scholar
Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T: A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun. 1999, 264: 847-854. 10.1006/bbrc.1999.1585.
Article
CAS
PubMed
Google Scholar
Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD: Overexpression of survivin initiates haematologic malignancies in vivo. Leukaemia. 2010, 24 (11): 1920-1926. 10.1038/leu.2010.198.
Article
CAS
Google Scholar
Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, Schützner J, Zatloukal P, Benkova K: Increased expression of inhibitor of apoptosis proteins, Survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol. 2009, 35 (6): 1449-1462.
Article
CAS
PubMed
Google Scholar
Fink SL, Cookson BT: Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005, 73 (4): 1907-1916. 10.1128/IAI.73.4.1907-1916.2005.
Article
PubMed Central
CAS
PubMed
Google Scholar
Shen XG, Wang C, Li Y, Wang L, Zhou B, Xu B, Jiang X, Zhou ZG, Sun XF: Downregulation of caspase-9 is a frequent event in patients with stage II colorectal cancer and correlates with poor clinical outcome. Colorectal Dis. 2010, 12 (12): 1213-1218. 10.1111/j.1463-1318.2009.02009.x.
Article
PubMed
Google Scholar
Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD, Mehta K: Downregulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002, 21 (57): 8843-8851. 10.1038/sj.onc.1206044.
Article
CAS
PubMed
Google Scholar
Fong PC, Xue WC, Ngan HYS, Chiu PM, Chan KYK, Tsao GSW, Cheung ANY: Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. J Clin Pathol. 2006, 59 (2): 179-183. 10.1136/jcp.2005.028027.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lavrik I, Golks A, Krammer PH: Death receptor signaling. J Cell Sci. 2005, 118: 265-267. 10.1242/jcs.01610.
Article
CAS
PubMed
Google Scholar
Friesen C, Fulda S, Debatin KM: Deficient activation of the CD95 (APO-1/Fas) system in drug resistant cells. Leukaemia. 1997, 11 (11): 1833-1841. 10.1038/sj.leu.2400827.
Article
CAS
Google Scholar
Fulda S, Los M, Friesen C, Debatin KM: Chemosensitivity of solid tumour cells in vitro is related to activation of the CD95 system. Int J Cancer. 1998, 76 (1): 105-114. 10.1002/(SICI)1097-0215(19980330)76:1<105::AID-IJC17>3.0.CO;2-B.
Article
CAS
PubMed
Google Scholar
Fulda S: Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol. 2010, 2010: 370835-
PubMed Central
PubMed
Google Scholar
Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG: Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynaecol Oncol. 2005, 96 (3): 705-713. 10.1016/j.ygyno.2004.10.046.
Article
CAS
Google Scholar
Rai KR, Moore J, Wu J, Novick SC, O'Brien SM: Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for replased/refractory chronic lymphocytic leukaemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study [abstract]. J Clin Oncol. 2008, 26: 7008-
Google Scholar
Abou-Nassar K, Brown JR: Novel agents for the treatment of chronic lymphocytic leukaemia. Clin Adv Haematol Oncol. 2010, 8 (12): 886-895.
Google Scholar
Kang MH, Reynolds CP, Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009, 15: 1126-1132. 10.1158/1078-0432.CCR-08-0144.
Article
PubMed Central
CAS
PubMed
Google Scholar
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005, 435 (7042): 677-681. 10.1038/nature03579.
Article
CAS
PubMed
Google Scholar
Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, Eastman A: Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and upregulating BH3-only protein NOXA. J Biol Chem. 2011, 286 (28): 24882-24895. 10.1074/jbc.M111.255828.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D: Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut. 2005, 54 (9): 1298-1308. 10.1136/gut.2004.056192.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wu X, Liu X, Sengupta J, Bu Y, Yi F, Wang C, Shi Y, Zhu Y, Jiao Q, Song F: Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. Indian J Exp Biol. 2011, 49 (2): 105-112.
CAS
PubMed
Google Scholar
Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumuors of patients with lung cancer. Nature Medicine. 1996, 2 (9): 985-991. 10.1038/nm0996-985.
Article
CAS
PubMed
Google Scholar
Chène P: p53 as a drug target in cancer therapy. Expert Opin Ther Patents. 2001, 11 (6): 923-935. 10.1517/13543776.11.6.923.
Article
Google Scholar
Suzuki K, Matusubara H: Recent advances in p53 research and cancer treatment. J Biomed Biotech. 2011, 2011: 978312-
Google Scholar
John Nemunaitis, Ian Ganly, Fadlo Khuri, James Arseneau, Joseph Kuhn, Todd McCarty, Stephen Landers, Phillip Maples, Larry Rome, Britta Randlev, Tony Reid, Sam Kaye, David Kirn: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 2000, 60: 6359-
Google Scholar
Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR: Targeted rescue of a destabilised mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA. 2008, 105 (30): 10360-10365. 10.1073/pnas.0805326105.
Article
PubMed Central
CAS
PubMed
Google Scholar
Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht A: Characterisation of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene. 2002, 21 (14): 2119-2129. 10.1038/sj.onc.1205362.
Article
CAS
PubMed
Google Scholar
Shangary S, Wang S: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 2008, 49: 223-241.
Article
CAS
Google Scholar
Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang : Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumours and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA. 2008, 105 (10): 3933-3938. 10.1073/pnas.0708917105.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ: Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008, 13 (5): 454-463. 10.1016/j.ccr.2008.03.004.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kuball J, Schuler M, Antunes Ferreira E, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wölfel T, Theobald M: Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther. 2002, 9 (13): 833-843.
Article
CAS
PubMed
Google Scholar
Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH: Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004, 53 (7): 633-641. 10.1007/s00262-003-0493-5.
Article
CAS
PubMed
Google Scholar
Vermeij R, Leffers N, van der Burg SH, Melief CJ, Daemen T, Nijman HW: Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J Biomed Biotechnol. 2011, 2011: 702146-
Article
PubMed Central
CAS
PubMed
Google Scholar
Dai Y, Lawrence TS, Xu L: Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Tranl Res. 2009, 1 (1): 1-15.
CAS
Google Scholar
Cao C, Mu Y, Hallahan DE, Lu B: XIAP and Survivin as therapeutic targets for radiation sensitisation in preclinical models of lung cancer. Oncogene. 2004, 23: 7047-7052. 10.1038/sj.onc.1207929.
Article
CAS
PubMed
Google Scholar
Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC: Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res. 2003, 9: 2826-2836.
CAS
PubMed
Google Scholar
Ohnishi K, Scuric Z, Schiesti RH, Okamoto N, Takahashi A, Ohnishi T: siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. Radiat Res. 2006, 166: 454-462. 10.1667/RR3606.1.
Article
CAS
PubMed
Google Scholar
Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Saitou Y, Sugimoto K, Nakano T: Targeting of X-linked inhibitor of apoptosis protein or Survivin by short interfering RNAs sensitises hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep. 2005, 12: 1211-1316.
Google Scholar
Grossman D, McNiff JM, Li F, Altieri DC: Expression and targeting of the apoptosis inhibitor, Survivin, in human melanoma. J Invest Dermatol. 1999, 113 (6): 1076-1081. 10.1046/j.1523-1747.1999.00776.x.
Article
CAS
PubMed
Google Scholar
Sharma H, Sen S, Lo ML Mraiggiò, Singh N: Antisense-mediated downregulation of antiapoptotic proteins induces apoptosis and sensitises head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther. 2005, 4: 720-727. 10.4161/cbt.4.7.1783.
Article
CAS
PubMed
Google Scholar
Du ZX, Zhang HY, Gao DX, Wang HQ, Li YJ, Liu GL: Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells. Exp Mol Med. 2006, 38: 230-240.
Article
CAS
PubMed
Google Scholar
Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S, Imamura M: Downregulation of Survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery. 2005, 138 (2): 299-305. 10.1016/j.surg.2005.05.009.
Article
PubMed
Google Scholar
Liu Q, Dong C, Li L, Sun J, Li C, Li L: Inhibitory effects of the survivin siRNA transfection on human lung adenocarcinoma cells SPCA1 and SH77. Zhongguo Fei Ai Za Zhi. 2011, 14 (1): 18-22.
CAS
PubMed
Google Scholar
Zhang X, Li N, Wang YH, Huang Y, Xu NZ, Wu LY: Effects of Survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP. Zhonghua Zhong Liu Za Zhi. 2009, 31 (3): 174-177.
CAS
PubMed
Google Scholar
Yang CT, Li JM, Weng HH, Li YC, Chen HC, Chen MF: Adenovirus-mediated transfer of siRNA against Survivin enhances the radiosensitivity of human non-small cell lung cancer cells. Cancer Gene Ther. 2010, 17: 120-130. 10.1038/cgt.2009.55.
Article
CAS
PubMed
Google Scholar
Pennati M, Folini M, Zaffaroni N: Targeting Survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007, 28 (6): 1133-1139. 10.1093/carcin/bgm047.
Article
CAS
PubMed
Google Scholar
Sun H, Liu L, Lu J, Qiu S, Yang CY, Yi H, Wang S: Cyclopeptide Smac mimetics as antagonists of IAP proteins. Bioorg Med Chem Lett. 2010, 20 (10): 3043-3046. 10.1016/j.bmcl.2010.03.114.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting AT, Wang S: Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther. 2011, 10 (5): 902-914. 10.1158/1535-7163.MCT-10-0864.
Article
PubMed Central
CAS
PubMed
Google Scholar
Rohn JL, Noteborn MH: The viral death effector Apoptin reveals tumour-specific processes. Apoptosis. 2004, 9: 315-322.
Article
CAS
PubMed
Google Scholar
Philchenkov A, Zavelevich M, Kroczak TJ, Los M: Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol. 2004, 26 (2): 82-97.
CAS
PubMed
Google Scholar
Yamabe K, Shimizu S, Ito T, Yoshioka Y, Nomura M, Narita M, Saito I, Kanegae Y, Matsuda H: Cancer gene therapy using a pro-apoptotic gene, caspase-3. Gene Ther. 1999, 6 (12): 1952-1959. 10.1038/sj.gt.3301041.
Article
CAS
PubMed
Google Scholar
Cam L, Boucquey A, Coulomb-L'hermine A, Weber A, Horellou P: Gene transfer of constitutively active caspase-3 induces apoptosis in a human hepatoma cell line. J Gene Med. 2005, 7 (1): 30-38. 10.1002/jgm.636.
Article
CAS
PubMed
Google Scholar
Li X, Fan R, Zou X, Gao L, Jin H, Du R, Xia L, Fan D: Inhibitory effect of recombinant adenovirus carrying immunocaspase-3 on hepatocellular carcinoma. Biochem Bioohys Res Commun. 2007, 358 (2): 489-494. 10.1016/j.bbrc.2007.04.134.
Article
CAS
Google Scholar